HC Wainwright started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX – Free Report) in a report published on Thursday, MarketBeat Ratings reports. The firm issued a neutral rating on the stock.
Avalo Therapeutics Price Performance
NASDAQ AVTX opened at $14.44 on Thursday. The firm has a 50-day moving average price of $9.47 and a two-hundred day moving average price of $11.23. Avalo Therapeutics has a 12-month low of $3.95 and a 12-month high of $34.46.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($14.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.70) by ($7.37). On average, research analysts predict that Avalo Therapeutics will post -7.78 EPS for the current year.
Institutional Investors Weigh In On Avalo Therapeutics
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Articles
- Five stocks we like better than Avalo Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Investing in Construction Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- The How and Why of Investing in Gold Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.